Delcath Systems, Inc. — FY2012 Form 10-K Summary
Business context and reporting period
Delcath is an oncology specialty pharmaceutical and medical-device company developing the CHEMOSAT/Melblez Kit system for high-dose regional chemotherapy and extracorporeal filtration, initially targeting primary and metastatic liver cancers. The filing covers the fiscal year ended December 31, 2012, including fourth-quarter results. The company transitioned from development-stage operations toward early commercialization in Europe.
- Generation Two CHEMOSAT for melphalan received CE Mark authorization in April 2012; the doxorubicin system satisfied CE Mark requirements in October 2012.
- The U.S. Melblez Kit NDA was submitted in August 2012, accepted for filing on October 15, 2012, and assigned a standard-review PDUFA goal date of June 15, 2013.
- Sixteen European cancer centers had entered training and marketing arrangements; eight were trained and activated by year-end.
- The system had been used in approximately 200 patients through clinical development and early European commercial experience.
Financial results and key metrics
| Metric | FY2012 | FY2011 | Change |
|---|---|---|---|
| Revenue | $0.346 million | $0 | First commercial sales |
| Cost of goods sold | $0.039 million | $0 | New in 2012 |
| Gross profit | $0.307 million | $0 | Gross margin approximately 88.7% |
| Selling, general and administrative expense | $27.963 million | $21.283 million | Up approximately 31% |
| Research and development expense | $26.215 million | $25.173 million | Up approximately 4% |
| Operating loss | $53.871 million | $46.456 million | Worsened approximately 16% |
| Net loss | $51.868 million | $30.885 million | Worsened approximately 68% |
| Basic and diluted loss per share | $0.85 | $0.68 | Loss increased |
| Net cash used in operating activities | $50.006 million | $37.372 million | Use increased $12.634 million |
| Cash and cash equivalents at year-end | $23.726 million | $25.777 million | Down $2.051 million |
| Total assets | $30.474 million | $35.241 million | Down approximately 14% |
| Stockholders’ equity | $20.009 million | $26.104 million | Down approximately 23% |
FY2012 operating expenses totaled $54.178 million. The reported net loss included a $2.159 million gain from the change in fair value of warrant liabilities, a non-cash item, compared with a $15.566 million gain in 2011. The filing does not provide a clear fourth-quarter revenue or gross-profit figure. Fourth-quarter operating loss was $11.825 million and net loss was $10.657 million, or $0.14 per share.
At December 31, 2012, current liabilities were $10.156 million, including a $3.427 million warrant liability and $0.309 million of deferred revenue. The company had no borrowings outstanding under its $20 million Silicon Valley Bank revolving facility, subject to borrowing-base and cash requirements. Operating lease obligations totaled approximately $11.2 million, and future minimum lease payments were reported at approximately $6.8 million for 2013 through 2017.
Material changes versus prior comparable period
- Revenue began in 2012 with approximately $0.4 million of European CHEMOSAT sales; approximately $30,000 remained deferred pending fulfillment of distribution obligations.
- SG&A increased by $6.680 million, primarily reflecting European commercialization, sales and support staffing, and related infrastructure.
- R&D increased by $1.042 million, including work on Generation Two filters, doxorubicin development, regulatory activities, and European medical-science-liaison deployment.
- Operating cash use increased by $12.634 million because of NDA costs, European commercialization, increased staffing, and development activities.
- The company raised approximately $45.058 million from stock sales and exercises of options and warrants, including approximately $21.1 million net from the May 2012 offering.
- Common shares outstanding increased to approximately 76.8 million at year-end from approximately 48.2 million at December 31, 2011, excluding additional potential dilution from options and warrants.
- Inventory increased to $1.105 million and accounts receivable to $0.144 million as commercial activity commenced; both balances were zero at year-end 2011.
Guidance, outlook, risks and unusual items
- Management expected continued losses and believed existing capital resources were sufficient to fund operations through 2013, but stated that additional working capital would likely be required for continued operations and full U.S. commercialization.
- If FDA approval were obtained by the June 15, 2013 PDUFA date, management anticipated launching U.S. commercialization efforts in the fourth quarter of 2013 and expected a REMS program requiring procedure-team training.
- Management planned additional clinical trials in hepatocellular carcinoma, colorectal cancer, and neuroendocrine tumors, subject to FDA discussions and successful development.
- European commercialization remained dependent on country-specific reimbursement, physician adoption, training, and the separate availability and prescribing of melphalan.
- Major risks include FDA non-approval or delay, limited clinical and commercial experience, continuing negative cash flow, the need for additional financing, reimbursement uncertainty, manufacturing and sole-source supply constraints, product liability, competition, intellectual-property challenges, and possible dilution from future equity issuance and warrant exercises.
- The company’s only product platform is the CHEMOSAT/Melblez Kit system; failure to commercialize it could leave the company without meaningful operating revenue.
- Subsequent to year-end through February 28, 2013, the company sold approximately 14.2 million shares under its at-the-market program for approximately $20.9 million before related expenses; no proceeds remained under that program.
- Ernst & Young issued unqualified opinions on the consolidated financial statements and internal control over financial reporting.
Important facts for investors to verify
- Whether the FDA approved, delayed, or issued a complete response to the Melblez Kit NDA and the ultimate scope of any approval.
- Actual European procedure volumes, realized pricing, gross margins, reimbursement status, and deferred-revenue recognition.
- Cash burn, cash runway, availability and terms of additional financing, and compliance with the SVB revolving-facility conditions.
- Potential dilution from the 2009 and 2012 warrants, stock options, the Terrapin purchase agreement, and other equity programs.
- Clinical-trial safety and efficacy data, including whether planned additional indications progress beyond early-stage development.
- Supply continuity for melphalan, sole-source components, sterilization services, and the company’s ability to scale compliant manufacturing.